PerkinElmer closes $5.25B BioLegend acquisition; issues ~14.1M shares as stock consideration

REVVITY, INC.

Aggregate purchase price ~$5.25B; paid 59.5% cash and 40.5% stock valued at $156.3561/share.
Cash funded by $2.28B notes offering, $500M term loan draw, ~$300M revolver draw, and cash on hand.
Transaction closed on September 17, 2021; previously announced on July 25, 2021.
Issued 14,066,771 shares of common stock in a private placement to BioLegend stockholders.
Financial statements and pro forma information to be filed by amendment within 71 days.

item 2.01 item 1.01 item 2.03 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.